Unfortunately worse than I thought when I commented in the other thread @sharebroker1.
At 31 December: $3.75M of cash and receivables due ($12.68M) of trade payables - per annual report these are normally 30-45 day terms Thereafter: $4.5M received from Chemphys $1.5M taken from Acuity
Still looking like they'll be about ($2.93M) in a hole, so unless they close that funding within their timeframe (end of March) they'll have to issue more shares to creditors and keep tapping the ATM, and that's just to clear their current bills - not considering the normal BAU corporate costs. Considering they've not fundamentally progressed development since early July 2024, it is quite incredible that since then they have increased the share count 76%, from 473.9M (30 June 24) to 834.3M (today).
(note this chart from Koyfin doesn't have the correct number of shares out)
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)